Embed Size (px)
Citation preview
LIN COLN PHARMACEUTICALS LTD.
HEALTHCARE FOR ALL
Date: October 22, 2019
To, To, The Manager, Listing Department,
The Department of Corporate Service, BSE LIMITED (BSE) pt Floor, New Trading Ring, National Stock Exchange of India Limited, (NSE)
Exchange Plaza, C-1, Block-G, Bandra-Kurla Complex, Bandra E , Mumbai-400051.
Rotunda Building, Phiroze Jeejeebhoy Tower, Dalal Street, Mumbai-400 001.
SYMBOL - LINCOLN Seri Code - 531633
Dear Sir,
SY.h.u. Press Release.
Please find enclosed a copy of press release dated October 22, 2019 titled "Lincoln Pharmaceuticals Limited receives a Patent for Diclofenac Rectal Spray."
The contents of the press release give full details,-. --
Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large and available on website of the Company i.e. www.lincolnpharma.com.
Thanking you,
Yours faithfully, FOR LINCOLN PHARMACEUTICALS LIMITED
(Authorised Signatory)
Encl. : As above
Regd. Office: "Lincoln House", Science City Road , Sola, Ahmedabad-380 060. Gujarat, Ind ia Phone: +91-79-4107 BODO I Fax: +91-79-4107 8062 I CIN L24230GJ1995PLC0242B8 E-mail: [email protected] I Website: www.lincolnpharma.com
Factory : 10, 12. 13, Trimul Estate. Near Kha traj Chokadi. P.O. Khatraj-382721. Ta. : Kalol, Dist. Gandh inagar, IGuj.J Phone: +91-79-49135000 E-mail: [email protected]
~~ ~~· UKAS \~,, .. ~ ........ ...
LINCOLN PHARMACEUTICA L S LTD.
HEALTHCARE FOR ALL
Media Release
Lincoln Pharmaceuticals Limited receives a Patent for Diclofenac Rectal Spray
A novel solution will offer better absorption of the drug resulting in quick relief and faster recovery to patients suffering from pre and postoperative pain, gynaecological surgery and musculoskeletal disorders
Highlights:·
> Lincoln Pharmaceuticals Limited becomes the first healthcare company to launch Diclofenac Rectal Spray formulation; Company will soon apply for a Global Patent
> Company will launch the product in the Indian market by Jan 2020; Looks to export in African, Latin America and Southeast Asia markets and expand to other markets
> Studies of clinical trials suggest Die ofenac rectal spray is highly effective in patients suffering from pre and postoperative pain, gynaecological surgery and musculoskeletal disorders associated with arthritis, acute pain
> Diclofenac Rectal Suppository market is Rs. 20 crore in India and growing at 16% per annum.
October 22, 2019: Ahmedabad based leading healthcare company, Lincoln Pharmaceuticals Limited is awarded a patent for its liquid Diclofenac Metered-Dose Rectal Spray (Diclofenac Rectal Spray). The patent has been awarded by the Government of India for "A Novel Liquid Rectal Spray Dosage Form Containing Diclofenac and Its Pharmaceutically Active Salts", Patent number -IN320894. This Patent is valid for 20 years. The company has necessary approvals from Drug Cont roller General of India (DCGI) and planning to launch it in the Indian market by January 2020. The E:ompany is also planning to apply for a Global Patent for this novel solution.
Lincoln Pharma's Liquid rectal spray dosage offers faster and better absorption of d ie drug res ulting in quick relief and speedy recovery to patients compared to the existing therapeutic options. Clinical Trials conducted suggest that Diclofenac Rectal Spray is highly effective in patients suffering from pre and postoperative pain, gynaecological surgery and musculoskeletal disorders such as muscular pain, pain associated with arthritis, acute pain in renal colic and mild body ache.
Speaking on this development, Mr. Maheni:Jra Patel, Managing Director, Lincoln Pharmaceuticals Limited, said, Globally, No liquid formulation of ~iclofenac for rectal administration is available. Lincoln Pharma will be the first company to introduce this novel solution aimed at better patient compliance, rapid drug release and greater bioavailability. We have developed this formulation with Diclofenac Sodium BP 25% WN, each squirt delivers Diclofenac Sodium 50 mg, Non-steroidal Anti-inflammatory Agent (NSAIDs). Due to this innovation, now patients can get far better results bY. using Diclofenac Rectal Spray as compared to the existing Diclofenac Suppository available in the market.
Diclofenac Rectal Suppository market is Rs. 20 crore in India and growing at 16% per annum. The company see huge export potential for this product and will start product registration in markets including African continents, Latin America and Southeast Asian markets and gradually expand to other markets.
Factory : 10. 12. 13. Trimul Es ta te. Near Khat raj Chokadi. P.O. Kha traj-38 2721. Ta.: Kalal. Dist. Gandhinagar. IGuj .) Phone: +91-79-49135000 E-mail: khatraj @l lincolnpharma.com
